Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 69articles · 30d
- 1+ day agolatest article
- Aug 18, 2026earliest in window
- 94%with images
- 224avg words
- Business & Industrial 47
- Medical 40
- Economy, Business & Finance 32
- Health 20
- Health & Wellness 20
- Finance & Business 19
- Science & Technology 15
- Science & Nature 5
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Trusted Research Environments Are Reshaping Real-World Data Access: Q&A with Mark Cziraky
6+ day, 20+ hour ago (497+ words) Pharmaceutical Executive The pharma and biotech industries run on data, especially on the R&D side Data is one of the most valuable assets, but it can also cause some of the biggest headaches Due to the wide array of…...
Why Payers Are Shifting Away from Licensing Out RWD
1+ week, 4+ day ago (304+ words) Carelon Research's Mark Cziraky on why bringing compute to data — not moving data — reduces risk and accelerates real-world evidence generation. The pharma and biotech industries run on data, especially on the R&D side. Data is one of the most…...
The Industry???s Shift on RWD
1+ week, 6+ day ago (247+ words) Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments. The pharma and biotech industries run on data, especially on the R&D side. Data is one of the…...
Exec on Execs: Compliance Burdens
1+ week, 6+ day ago (67+ words) Pharmaceutical Executive Exec on Execs: Compliance Burdens The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals FDA Approves Daraxonrasib as…...
The AI Implementations That Produce Real Business Value
2+ week, 4+ day ago (296+ words) Pharmaceutical Executive Over recent years, the pharmaceutical industry has generally embraced AI Due the nature of the technology, various companies has implemented it across multiple sectors Now, the question that everyone is asking is: where is AI having an actual…...
Focusing on Asset Acquisition Over Building a Single Platform Technology
2+ week, 6+ day ago (199+ words) Pharmaceutical Executive Earlier this year, Pharmaceutical Executive reported on Chinaâs growing prominence in the pharma and biotech spaces During this year, billions of dollars have been committed to licensing commitments with Chinese companies, with many US-based companies making up…...
Targeted Resilience: A Smarter Tariff Response | PharmExec
3+ week, 3+ day ago (49+ words) Targeted Resilience: A Smarter Tariff Response Pharmaceutical Executive What Are the Specific Metrics to Look for Following the Tariff Announcement? Pharmaceutical Executive: August 2026 Interactive Digital Edition The Operational Reality of Reshoring Pharma Manufacturing: Q&A with Rohit Tripathi How to…...
When Drug Pricing Becomes Trade Policy
3+ week, 4+ day ago (1614+ words) How drug pricing, tariffs, and manufacturing decisions are becoming connected. For years, pharmaceutical companies could treat U.S. reimbursement, European market access, trade policy and manufacturing strategy as related but mostly separate issues. That separation is becoming harder to defend. The Administration…...